マサムネ　ケン   Masamune Ken   正宗　賢    所属   医学研究科 医学研究科 (医学部医学科をご参照ください)    職種   教授
言語種別	英語
発表タイトル	First-in-human Clinical Trial of Sonodynamic Therapy with Drug Delivery System
会議名	5th COINS Symposium Shaping a dream! In-body hospitals -Future hearth care created by Kawasaki ventures-
発表形式	ポスター掲示
発表者・共同発表者	◎HORISE Yuki, OKAMOTO Jun, KONISHI Yoshiyuki, TAKEMAE,Kazuhisa Kazuhisa, KUSUDA Kaori, IZUMI Mikio , IKUTA Soko, MASAMUNE Ken, ISEKI Hiroshi, NISHIYAMA Nobuhiro , KATAOKA Kazunori, MURAGAKI Yoshihiro
発表年月日	2018/12/14
開催地 （都市, 国名）	Kawasaki
学会抄録	5th COINS Symposium 47
概要	Sonodynamic therapy (SDT) uses a chemical sonosensitizer in combination with high- intensity focused ultrasound (HIFU), and it would reduce the reduction of drug dose and HIFU irradiation power compared to those of conventional monotherapies. From our previous study of four pet dogs with spontaneous tumors including osteosarcoma, hepatocellular cancer, and prostate cancer, the usefulness of SDT using an anticancer micelle (NC-6300) was confirmed. Based on the results, a clinical study involving the application of SDT method in humans was recently conducted at Tokyo Medical University. SDT method was used to treat human patients with unresectable, intractable cancers, such as pancreatic and biliary tract cancer, to evaluate its safety under set fixed conditions, including the dosage of NC-6300 and the output power of HIFU irradiation. While continuing a research into clarifying the action mechanism of this SDT approach such as radical oxygen, we plan to conduct an investigator-initiated clinical trial to evaluate the efficacy of SDT. This therapy has the potential to become a standard therapy and contribute to the treatment of both pet and human cancers.